These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 21623265)

  • 1. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
    Ou SH; Kwak EL; Siwak-Tapp C; Dy J; Bergethon K; Clark JW; Camidge DR; Solomon BJ; Maki RG; Bang YJ; Kim DW; Christensen J; Tan W; Wilner KD; Salgia R; Iafrate AJ
    J Thorac Oncol; 2011 May; 6(5):942-6. PubMed ID: 21623265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
    Ou SH
    Drug Des Devel Ther; 2011; 5():471-85. PubMed ID: 22162641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.
    Ou SH; Bartlett CH; Mino-Kenudson M; Cui J; Iafrate AJ
    Oncologist; 2012; 17(11):1351-75. PubMed ID: 22989574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
    Jänne PA; Shaw AT; Camidge DR; Giaccone G; Shreeve SM; Tang Y; Goldberg Z; Martini JF; Xu H; James LP; Solomon BJ
    J Thorac Oncol; 2016 May; 11(5):737-747. PubMed ID: 26899759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crizotinib resistance: implications for therapeutic strategies.
    Dagogo-Jack I; Shaw AT
    Ann Oncol; 2016 Sep; 27 Suppl 3(Suppl 3):iii42-iii50. PubMed ID: 27573756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
    Casaluce F; Sgambato A; Maione P; Rossi A; Ferrara C; Napolitano A; Palazzolo G; Ciardiello F; Gridelli C
    Target Oncol; 2013 Mar; 8(1):55-67. PubMed ID: 23325296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
    Kwak EL; Bang YJ; Camidge DR; Shaw AT; Solomon B; Maki RG; Ou SH; Dezube BJ; Jänne PA; Costa DB; Varella-Garcia M; Kim WH; Lynch TJ; Fidias P; Stubbs H; Engelman JA; Sequist LV; Tan W; Gandhi L; Mino-Kenudson M; Wei GC; Shreeve SM; Ratain MJ; Settleman J; Christensen JG; Haber DA; Wilner K; Salgia R; Shapiro GI; Clark JW; Iafrate AJ
    N Engl J Med; 2010 Oct; 363(18):1693-703. PubMed ID: 20979469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
    Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
    Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
    Solomon BJ; Mok T; Kim DW; Wu YL; Nakagawa K; Mekhail T; Felip E; Cappuzzo F; Paolini J; Usari T; Iyer S; Reisman A; Wilner KD; Tursi J; Blackhall F;
    N Engl J Med; 2014 Dec; 371(23):2167-77. PubMed ID: 25470694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
    Chen RL; Zhao J; Zhang XC; Lou NN; Chen HJ; Yang X; Su J; Xie Z; Zhou Q; Tu HY; Zhong WZ; Yan HH; Guo WB; Wu YL; Yang JJ
    BMC Cancer; 2018 Nov; 18(1):1171. PubMed ID: 30477470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer.
    Feng Y; Minca EC; Lanigan C; Liu A; Zhang W; Yin L; Pennell NA; Farver C; Tubbs R; Ma PC
    J Thorac Oncol; 2014 May; 9(5):646-53. PubMed ID: 24722154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
    Ou SH; Bazhenova L; Camidge DR; Solomon BJ; Herman J; Kain T; Bang YJ; Kwak EL; Shaw AT; Salgia R; Maki RG; Clark JW; Wilner KD; Iafrate AJ
    J Thorac Oncol; 2010 Dec; 5(12):2044-6. PubMed ID: 21102269
    [No Abstract]   [Full Text] [Related]  

  • 16. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
    Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A
    Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene.
    Shiraishi T; Yamasaki K; Kidogawa M; Shingu T; Ujimiya F; Jotatsu T; Matsumoto S; Izumi H; Nishida C; Goto K; Yatera K
    Intern Med; 2023 Nov; 62(21):3215-3221. PubMed ID: 36927974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer.
    Kinoshita Y; Koga Y; Sakamoto A; Hidaka K
    BMJ Case Rep; 2013 Sep; 2013():. PubMed ID: 24022905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
    Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
    Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib targets in glioblastoma stem cells.
    Junca A; Villalva C; Tachon G; Rivet P; Cortes U; Guilloteau K; Balbous A; Godet J; Wager M; Karayan-Tapon L
    Cancer Med; 2017 Nov; 6(11):2625-2634. PubMed ID: 28960893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.